Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Lifesciences Corp.

www.edwards.com

Latest From Edwards Lifesciences Corp.

MTI 100: Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups

In Medtech Insight's latest rankings of top 100 revenue-earners in the medical device and diagnostics sector, it was steady as she goes for most of the multinational medtechs, with some major exceptions. But there will be more M&A reflected in next year's ranking based on 2018 revenues. Also, medtech groups leading the global market tightened their grip further in 2017, as providers chose to partner more and more with fewer suppliers who can offer a wider provision of services.

Commercial M & A

Global Device Approvals, Weekly Snapshot: Medtronic, Edwards Wins In Europe

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. CE marks for a Medtronic stent graft and Edwards Lifesciences' TAVR update anchor this week's list.

Approvals Innovation

Latest Sapien Valve Gets EU Go-Ahead, But Germany Will Have To Wait

Edwards Lifesciences plans a "controlled rollout" of its Sapien 3 Ultra transcatheter heart valve replacement in Europe following the CE mark announced Nov. 16. But a patent dispute with Boston Scientific will prevent Edwards from launching it in Germany.

Approvals Cardiology

German Court Rules For Boston Scientific In TAVR Patent Tiff

A German court has issued a preliminary ruling favoring Boston Scientific in its most recent intellectual property dispute with Edwards LifeSciences. The ruling would allow Boston Scientific to block Edwards’ Sapien 3 Ultra from the German market.

Medical Device Cardiology
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register